Heart Metabolics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Out of Business

Heart Metabolics General Information

Description

Developer of pharmaceutical therapy designed to help in the treatment of hypertrophic cardiomyopathy (HCM). The company's therapy is used in developing perhexiline as a therapeutic for all types of treatment-related to HCM, enabling patients to get cured who are presently in search for the treatment.

Contact Information

Website
www.heartmetabolics.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 20B Beckett Way
  • Dublin 12
  • Ireland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 20B Beckett Way
  • Dublin 12
  • Ireland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Heart Metabolics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Nov-2017 Completed Out of Business
3. Later Stage VC 01-Jan-2015 Completed Generating Revenue
2. Later Stage VC (Series A) 17-Apr-2014 $20M $24M Completed Generating Revenue
1. Later Stage VC (Series A) 04-Jan-2013 $4M $4M Completed Generating Revenue
To view Heart Metabolics’s complete valuation and funding history, request access »

Heart Metabolics Patents

  • 31

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Heart Metabolics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2015147787-A Treatment of heart failure with normal ejection fraction Pending 01-Apr-2015
AU-2009346606-A1 Treatment of heart failure with normal ejection fraction Active 20-May-2009
AU-2009346606-B2 Treatment of heart failure with normal ejection fraction Inactive 20-May-2009
CA-2816448-A1 Treatment of heart failure with normal ejection fraction Inactive 20-May-2009
JP-2012527438-A Normal ejection fraction treatment for heart failure Pending 20-May-2009 A61K31/4458
To view Heart Metabolics’s complete patent history, request access »

Heart Metabolics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Heart Metabolics FAQs

  • When was Heart Metabolics founded?

    Heart Metabolics was founded in 2004.

  • Where is Heart Metabolics headquartered?

    Heart Metabolics is headquartered in Dublin, Ireland.

  • What is the size of Heart Metabolics?

    Heart Metabolics has 6 total employees.

  • What industry is Heart Metabolics in?

    Heart Metabolics’s primary industry is Drug Discovery.

  • Is Heart Metabolics a private or public company?

    Heart Metabolics is a Private company.

  • What is Heart Metabolics’s current revenue?

    The current revenue for Heart Metabolics is .

  • How much funding has Heart Metabolics raised over time?

    Heart Metabolics has raised $40.7M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »